Releases


All 2014 Releases
Dec 19, 2014 Veloxis Comments on U.S. District Court Order  
Dec 19, 2014 Veloxis kommenterer kendelse fra amerikansk distriktsdomstol  
Dec 16, 2014 Veloxis offentliggør at have anlagt retssag mod de amerikanske sundhedsmyndigheder FDA med påstand om, at FDA skal tilpligtes at udstede endelig godkendelse af Envarsus® XR.  
Dec 16, 2014 Veloxis announces that it has filed an action against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.  
Dec 16, 2014 Veloxis Pharmaceuticals offentliggør finanskalendar for 2015  
Dec 16, 2014 Veloxis Pharmaceuticals Announces Financial Calendar for 2015  
Nov 17, 2014 Veloxis Announces Publication of Phase III Study of Once Daily Envarsus® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients  
Nov 17, 2014 Warrant Programme - New Articles of Association  
Nov 17, 2014 Warrantordning - Nye vedtægter  
Nov 12, 2014 Veloxis Pharmaceuticals A/S etablerer warrantordning  
Nov 12, 2014 Veloxis Pharmaceuticals A/S establishes new Warrant Programme  
Nov 12, 2014 Veloxis Pharmaceuticals announces financial results for the first nine months of 2014 and improves the full year outlook  
Nov 7, 2014 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2014 — results from 1 January to 30 September, 2014  
Nov 7, 2014 Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 3. kvartal 2014 — resultater fra 1. januar til 30. september 2014  
Oct 31, 2014 Veloxis Pharmaceuticals A/S to Host Conference Call discussing the FDA tentative approval of Envarsus® XR  
Oct 31, 2014 Veloxis Pharmaceuticals A/S er vært for en telekonference for at diskutere den foreløbige godkendelse af Envarsus® XR  
Oct 31, 2014 Veloxis announces tentative approval of Envarsus® XR  
Oct 31, 2014 Veloxis modtager foreløbig godkendelse for Envarsus® XR  
Sep 2, 2014 Warrantordning - Nye vedtægter  
Sep 2, 2014 Warrant Programme - New Articles of Association  
Sep 1, 2014 Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise  
Sep 1, 2014 Warrant Program - Registrering af kapitalforhøjelse og nye vedtægter i forlængelse af warrantudnyttelse  
Sep 1, 2014 Warrantprogram - Veloxis Pharmaceuticals A/S udsteder nye aktier i forbindelse med udnyttelse af warrants  
Sep 1, 2014 Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants  
Aug 20, 2014 Veloxis Pharmaceuticals A/S establishes new Warrant Programme  
Aug 20, 2014 Veloxis Pharmaceuticals A/S etablerer warrantordning  
Aug 20, 2014 Veloxis Pharmaceuticals announces financial results for the first six months of 2014  
Aug 15, 2014 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for second Quarter 2014 — results from 1 January to 30 June, 2014  
Aug 15, 2014 Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 2. kvartal 2014 — resultater fra 1. januar til 30. juni 2014  
Jul 28, 2014 Envarsus® Receives European Marketing Authorization for Treatment of Both Kidney and Liver Transplant Patients  
Jul 28, 2014 Envarsus® får EMA markedføringstilladelse til behandling af såvel nyre- som levertransplantationspatienter  
Jun 30, 2014 Envarsus® XR Demonstrates Lower Treatment Failure Rate in African-Americans Compared to Twice-Daily Tacrolimus (Prograf®)  
Jun 30, 2014 Envarsus® XR viser lavere forekomst af behandlingssvigt i afroamerikanere sammenlignet med to-gange-daglig tacrolimus (Prograf®)  
Jun 23, 2014 Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients  
Jun 23, 2014 Veloxis offentliggør positive 2-års resultater af pivotalt fase III studie af Envarsus® XR (tacrolimus extended-release tabletter) i de novo nyretransplantationspatienter  
Jun 3, 2014 Veloxis Announces Senior Level Appointments in Preparation for U.S. Commercialization of Envarsus® XR (tacrolimus extended-release tablets)  
May 22, 2014 Warrantordning - Nye vedtægter  
May 22, 2014 Warrant Programme - New Articles of Association  
May 22, 2014 Veloxis modtager positiv udtalelse fra CHMP for Envarsus® til behandling af såvel nyre- som levertransplantationspatienter  
May 22, 2014 Veloxis Receives Positive Opinion from CHMP for Envarsus® for Treatment of Both Kidney and Liver Transplant Patients  
May 14, 2014 Veloxis Pharmaceuticals A/S establishes new Warrant Programme  
May 14, 2014 Veloxis Pharmaceuticals A/S etablerer warrantordning  
May 14, 2014 Veloxis Pharmaceuticals announces financial results for the first three months of 2014  
May 6, 2014 Veloxis Pharmaceuticals A/S er vært for en telekonference i forbindelse med offentliggørelsen af kvartalsrapporten for 1. kvartal 2014 — resultater fra 1. januar til 31. marts 2014  
May 6, 2014 Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for first Quarter 2014 — results from 1 January to 31 March, 2014  
Apr 28, 2014 Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus® in Liver Transplant Patients  
Apr 28, 2014 Veloxis Announces Scientific Publication of Phase II Study Demonstrating Conversion from Twice-Daily Tacrolimus to Once-Daily Envarsus® in Liver Transplant Patients  
Apr 9, 2014 Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting  
Apr 9, 2014 Veloxis Pharmaceuticals A/S - Forløb af ordinær generalforsamling  
Mar 25, 2014 Warrantordning - Nye vedtægter  
Showing 1-50 of 71 Page: 1 2  Next 50
=add release to Briefcase